Ipsell's Stem Cell Therapy 'Mucon' Shows Promise in Osteoarthritis Treatment
• Ipsell's 'Mucon', an iPSC-derived cartilage regeneration treatment, demonstrated a 30% improvement in joint indicators in animal trials after a single infusion.
• Mucon is designed as an injectable treatment, offering a less invasive alternative to surgery for degenerative arthritis patients.
• Ipsell is preparing to initiate clinical trials for Mucon and aims for commercialization by 2030, targeting the large market of osteoarthritis patients.
• The company is also developing neuroregenerative treatments and cell-based anticancer drugs, alongside a disease modeling platform service.
© Copyright 2025. All Rights Reserved by MedPath